Introduction
In contrast with IgM and IgG, IgA antibodies are essentially non-inflammatory in their mode of action [l-31, a property that is probably of great importance for the maintenance of the integrity of mucosal surfaces as well as internal tissues. Inflammation is a complex and multifaceted process involving numerous lymphoid cells and immunological effector molecules, as well as cellular and non-cellular factors not normally regarded as part of the immune system, and is the physiological response of the body to damage Abbreviations used: ACP, alternative complement pathway; IL, interleukin; S-IgA, secretory IgA; TNF-a, tumour necrosis factor a.
inflicted by infectious or non-infectious agents. Recent thought has emphasized the role of inflammation in the initiation of the immune response, by inducing the generation of 'second signals' to lymphocytes [4,5], but inflammation is also a consequence of immune effector mechanisms in combating infection, as several products of the defence mechanisms have potent inflammatory effects. Thus inflammation is both beneficial and necessary, but because of its potential for inflicting tissue damage even greater than that caused by the direct action of pathogens, it must be regulated by homoeostatic mechanisms. When these fail, inflammatory disease may result and persist. IgA is the most heterogeneous of human immunoglobulins, as it occurs in multiple Volume 25 molecular forms (monomeric, polymeric and secretory) and subclasses (1 and 2) which are distributed differently between the circulatory and mucosal immune systems [6] . IgA antibodies may therefore have different functional properties depending on their precise molecular constitution, as well as the circumstances of their action.
IgA and complement
The concept that IgA represents a 'safe' form of anti-inflammatory antibody [7] is exemplified by the findings that intact native human IgA antibodies fail to activate complement by either major pathway when complexed with antigen [8] , and further that they powerfully interfere with complement activation by IgM and IgG antibodies [2, 9] . T h e frequently cited ability of IgA to promote turnover of the alternative complement pathway (ACP) (reviewed in [3]) on close examination turns out to be due to artificial aggregation or conformational alteration of IgA induced by exposure to denaturing agents during purification, heat, deposition on hydrophobic surfaces, chemical cross-linking or modification, or aberrant synthesis. However, there may be pathological (rather than physiological) relevance in this, for example, in IgA nephropathy, where it appears that IgAl deposited in the glomerular mesangium (where complement is activated) may be defective in the composition of its oligosaccharides particularly the 0-linked glycans of the hinge region [lo] . In particular, the cleavage of sialic acid, as well as other carbohydrate moieties, from IgA enhances its ability to promote ACP activation [ 111. Although carbohydrate residues are important for ACP activation [12] , terminal sialic acids inhibit ACP activation [13, 14] . T o the extent that opsonization of particulate antigens by antibodies depends on complement fixation, thereby engaging C3 receptors on phagocytes, interference with complement activation by IgA antibodies also diminishes phagocytosis and the release of reactive oxygen intermediates [ 151.
IgA and phagocytes
However, phagocytes (including monocytesl macrophages, neutrophils and eosinophils) express FcaR, which, at least under certain circumstances, is capable of mediating phagocytosis and transducing signals for oxidative metabolism and granule release . FcaR is a heterogeneous receptor that appears to be extensively and variably glycosylated depending in part on the cell type on which it is expressed [21, 22] , and its intracellular connections with signal-transducing systems are beginning to be elucidated [23] . Although FcaR is constitutively expressed on monocytes, neutrophils and eosinophils, it is up-regulated by certain cytokines. Exposure of neutrophils to tumour necrosis factor a (TNF-a) or interleukin (IL) -8 increases surface expression of FcaR and enhances their ability to respond to IgA-opsonized particles [ 15, 24, 25] . Tissue macrophages appear to express FcaR variably, and it is not known what regulates this expression, nor its functional significance [26] . In the case of neutrophils, which in their resting state appear to respond weakly if at all to IgAcomplexed antigen, it can be speculated that enhanced expression of FcaR on exposure to inflamamtory or chemotactic cytokines has functional significance within mucosal tissues such as the gut. IL-8 and TNF-a released by epithelial cells exposed to aggressive bacteria attract and activate neutrophils to a site of potential pathogenic challenge, and functional up-regulation of their FcaRs enables them to be effective phagocytes in the IgA-rich environment of the submucosa. It will be interesting to determine if such activated neutrophils respond to IgA in the same way, or not, as cells reacting to IgG and C3b, since it is clearly important that, in defending the mucosa against the threat of bacterial invasion, the collateral damage to the mucosa itself be strictly limited, or else the situation may be aggravated.
It is particularly noteworthy that IgA, especially secretory IgA (S-IgA), when coupled to agarose, is the most potent stimulus for eosinophi1 degranulation [ 181. As eosinophils occur frequently in mucosal tissues and are implicated in defence against metazoan parasites, this may be an important effector activity of IgA [27, 28] .
However, further work is necessary in this area, especially using IgA (and S-IgA) antibodies complexed with antigens to model more closely the physiological situation. With monocytes, an interesting picture is beginning to emerge. IgA has been shown to suppress the release of inflammatory cytokines (TNF-a and IL-6) by human monocytes exposed to lipopolysaccharide [29] . [38, 39] (Figure la) . According to the present hypothesis, if IgA antibodies are also present, they will suppress C3b fixation by the immune complex and thereby diminish its ability to stimulate B-cells to respond to take up the complex, and present the processed antigen to cognate T-cells ( Figure  lb) . At one time, it was suggested that IgA immune complexes could be responsible for the development and maintenance of oral tolerance [40] , although this was later reinterpreted as being due to other immunoglobulin isotypes, especially IgGl which in mice, interestingly, is a weak activator of complement [41] . Furthermore,
Figure I
Proposed model for suppression of B-cell signalling by antigen complexed with IgA antibody
In (a), antigen (Ag) is complexed with IgG which activates the classical complement pathway (CCP) resulting in the covalent association of C3b, which is subsequently cleaved to C3dg, with the complex. The B-cell recognizes antigen through its surface immunoglobulin (slg), and co-ligation of CR2 by C3dg enhances the signal transduction, which in turn leads to uptake, processing and presentation of the antigen as peptides associated with MHC class II molecules. In (b), the presence of IgA antibody in the immune complex interferes with the activation of complement so that C3b is not bound, and therefore the CR2 is not ligated. Recognition of the complex only through surface immunoglobulin results in a weak signal, unless antigen is present at much higher concentration. 
